CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Elmar Nurmemmedov, Ph.D.
Assistant Professor and Director of Drug Discovery
Saint John's Cancer Institute
Saint John's Health Center
Santa Monica, Calif.
In Person Seminar: CRISPR-guided Therapeutic Discovery: First-in-Class Inhibitors of CHD4 for Glioblastoma
Date: Oct. 29, 2021
Time: 11:00 a.m. - 12:00 p.m.
Archived video
About this Seminar
Glioblastoma is a highly aggressive form of brain cancer. Therapeutic intervention of glioblastoma through epigenetic shapers such as CHD4 is established as a promising avenue for clinical impact. Despite the accumulating evidence suggesting the importance of CHD4 in glioblastoma, little effort has been done to develop specific CHD4 inhibitors.
In his lab, Dr. Nurmemmedov and his team have taken a unique approach to targeting CHD4 in glioblastoma. They have designed a two-arm therapeutic discovery approach that combined tiling CRISPR screen together with rational chemical biology. The CRISPR study identified the therapeutically vulnerable sites of the CHD4 protein. On the other hand, using rigorous biology and chemistry, the team has identified several novel inhibitors of CHD4. They hypothesize that a selective CHD4 inhibitor would specifically impair tumor growth while sparing healthy cells and could potentially have a therapeutic application for glioblastoma. These inhibitors demonstrate selectivity, target engagement, and unique mechanism of action. Once fully investigated, these molecules could be used to prevent therapy resistance in glioblastomas, with potential translation to the clinic.
You May Also Be Interested In...
-
Home ItemSocial Learning in Borderline Personality Disorder , home
April 4, 2025, 11:00 a.m. | Sarah Fineberg, M.D., Ph.D., Assistant Professor, Department of Psychiatry, Yale School of Medicine | Co-Sponsored by the Fralin Biomedical Research Institute Center for Human Neuroscience Research
-
Home ItemBringing Precision Medicine to Psychiatry , home
April 10, 2025, 5:30 p.m. (Reception at 5 p.m.) | Jordan Smoller, M.D., Sc.D., Massachusetts General Hospital Trustees Endowed Chair in Psychiatric Neuroscience; Professor of Psychiatry, Harvard Medical School; Professor of Epidemiology, T.H. Chan Harvard School of Public Health; Director, Psychiatric and Neurodevelopmental Genetics Unit, Massachusetts General Hospital | Maury Strauss Distinguished Public Lecture
-
Home ItemExtracellular Vesicles in the Pathogenesis, Diagnosis and Treatment of the Heart , home
April 11, 2025, 11:00 a.m. | Susmita Sahoo, Ph.D., Associate Professor, Department of Medicine and Cardiology, Icahn School of Medicine at Mount Sinai | Co-Sponsored by the Fralin Biomedical Research Institute Center for Vascular and Heart Research
-
Home ItemA Human-Centric View of Cerebellar Development , home
April 18, 2025, 11:00 a.m. | Kathleen Millen, Ph.D., Professor, Department of Pediatrics/Genetics, Associate Director and Principal Investigator, Seattle Children's Hospital Research Institute, The University of Washington School of Medicine | Co-Sponsored by the Center for Neurobiology Research, Fralin Biomedical Research Institute
-
Home ItemMolecular and Neurobiological Studies in Rett Syndrome and Other MECP2 Disorders , home
May 1, 2025, 5:30 p.m. (Reception at 5 p.m.) | Huda Zoghbi, M.D., Professor, Pediatrics, Molecular and Human Genetics, Neuroscience, and Neurology; Director, Jan and Dan Duncan Neurological Research Institute, Baylor College of Medicine; Member, National Academy of Medicine | Maury Strauss Distinguished Public Lecture
-
Home ItemA Novel Bispecific Antibody to Target the Brain Tumor Microenvironment , home
May 2, 2025, 11:00 a.m. | Khuson Yun, Ph.D., Associate Professor, Department of Neurology, Houston Methodist Chair, Neurodegenerative Disease Research, Houston Methodist Research Institute, Weill Cornell Medical College | Co-Sponsored by the Fralin Biomedical Research Institute Cancer Research Center – Roanoke